Lineage Point Capital LP Invests $3.33 Million in Drugs Made In America Acquisition II Corp. $DMII

Lineage Point Capital LP bought a new position in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 336,360 shares of the company’s stock, valued at approximately $3,330,000. Drugs Made In America Acquisition II accounts for about 1.3% of Lineage Point Capital LP’s holdings, making the stock its 28th largest holding.

Several other large investors have also recently bought and sold shares of DMII. Geode Capital Management LLC acquired a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $265,000. Virtu Financial LLC acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter worth approximately $317,000. ABC Arbitrage SA bought a new stake in Drugs Made In America Acquisition II in the 4th quarter valued at $396,000. Deltec Asset Management LLC acquired a new position in Drugs Made In America Acquisition II in the 4th quarter valued at $495,000. Finally, Royal Bank of Canada bought a new position in Drugs Made In America Acquisition II during the 4th quarter worth $655,000.

Drugs Made In America Acquisition II Stock Performance

Drugs Made In America Acquisition II stock opened at $10.10 on Friday. The business’s fifty day moving average is $10.04. Drugs Made In America Acquisition II Corp. has a one year low of $9.86 and a one year high of $10.10.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Wall Street Zen raised Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.